期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

雌激素药物中间体6-酮雌二醇的合成 被引量：3

Synthesis of Estrogen Drug Intermediate 6-Oxo-estradiol
下载PDF
导出
摘要 以雌酚酮为起始原料,经硼氢化钠还原制得17β-雌二醇,再经乙酸酐酰化保护羟基和三氧化铬氧化得到3,17-二乙酰基-6-酮-17β-雌二醇,最后经氢氧化钾水溶液水解合成了雌激素药物中间体6-酮雌二醇,总收率38.0%,其结构经1H NMR确证。 3,17-diacetyl-6-oxo-17β-estradiol（5） was prepared from commercially available estrone followed by reduction with NaBH4,acylation with acetic anhydride for protecting hydroxyl and oxidation with CrO3.Then 5 was hydrolyzed by KOH to give an important intermediate of estrogen drug,6-oxo-estradiol in total yield of 38.0%.The structure was confirmed by 1H NMR.
作者 梁占超 钟燕 刘靖 张首国 彭涛 温晓雪 许丹科 王林
机构地区 军事医学科学院放射与辐射医学研究所
出处 《合成化学》 CAS CSCD 北大核心 2011年第3期428-429,432,共3页 Chinese Journal of Synthetic Chemistry
基金 国家自然科学基金资助项目(30770655 30472081 81072531)
关键词 6-酮雌二醇 药物中间体 雌二醇 合成 6-oxo-estradiol drug intermediate estradiol synthesis
分类号 O629.2 [理学—有机化学] R914.5 [医药卫生—药物化学]
  • 相关文献

参考文献9

  • 1Henke B R, Heyer D. Recent advances in estrogen receptor modulators [ J ]. Curr Opin Drug Discov Devel, 2005,8(4) :437 -438.
  • 2冯长根,邓霞飞,向华,廖清江.治疗乳腺癌的抗雌激素药物研究进展[J].中国新药杂志,2006,15(13):1051-1057. 被引量：13
  • 3安富荣,崔岚,祝德秋.纯抗雌激素Fulvestrant的研究进展[J].中国临床药理学杂志,2002,18(2):156-158. 被引量：4
  • 4张涛,李少林.乳腺癌内分泌治疗新进展[J].内分泌外科杂志,2008,2(2):123-126. 被引量：4
  • 5Shevchenko V P, Nagaev I Y, Shevchenko K V, et al. Synthesis of steroid hormones highly labeled with tritium and their use for assessing the activity of aromatase [ J ]. Radiochemistry,2006,46 (5) :494 - 499.
  • 6Banerjee S, Das T, Chakraborty S, et. al. An estradiol-eonjugate for radlolabelling with 177Lu: An attempt to prepare a radiotherapeutic agent [ J ]. Bioorg Med Chem,2005,13(13) :4315 -4322.
  • 7李键,周乐,刘智喜.Corey氧化剂在6－酮－17β－雌二醇合成中的应用[J].化学试剂,1994,16(5):317-318. 被引量：2
  • 8Schwenk E, Montclair. Oxygenated estrogenic hormones and method of preparing same [ P]. US 2 294 938,1942.
  • 9Corey E J, Suggs J W. Pyfidinium chlorochromate. An efficient reagent for oxidation of primary and secondary alcohols to carbonyl compounds [ J ]. Tetrahedron Lett, 1975,16(31 ) :2647 -2650.

二级参考文献34

  • 1金炎.Faslodex申请美国许可证[J].国外药讯,2001,7:23-23.
  • 2HENKE BR,HEVER D.Recent advances in estrogen receptor modulators[J].Curr Opin Drug Devel,2005,8(4):437-448.
  • 3ELKAK AE,MOKBEL K.Pure antiestrogens and breast cancer[J].Curr Med Res Opin,2001,17(4):282 -289.
  • 4YOUNUS J,VANDENBERG TA.A practical overview of aromatase inhibitors in postmenopausal women with hormone receptor-positive breast cancer[J].Bull Cancer,2005,92 (4):E39-E44.
  • 5BUZDAR AU.Fulvestrant:a new type of estrogen receptor antagonist for the treatment of advanced breast cancer[J].Drugs Today,2004,40(9):751 -764.
  • 6BRUCE HM,COHEN FJ.Selective estrogen receptor modulators:alook ahead[J].Drugs,1999,57(5):653 -663.
  • 7BRZOZOWSKI AM,PIKE ACW,DAUTER Z,et al.Molecular basis of agonism and antagonism in the oestrogen receptor[J].Nature,1997,389(6652):753 -758.
  • 8DOWSETT M,NICHOLSON RI,PIETRAS RJ.Biological characteristics of the pure antiestrogen fulvestrant:overcoming endocrine resistance[J].Breast Cancer Res Treat,2005,93(Suppl1):S11-S18.
  • 9FISHER B,COSTANTINO JP,WICKERHAM DL,et al.Tamoxifen for prevention of breast cancer:report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study[J].J Natl Cancer Iust,1998,90(18):1371-1388.
  • 10FISHER B,DIGNAM J,BRYANT J,et al.Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors[J].J Natl Cancer Inst,1996,88(21):1529-1542.

共引文献18

同被引文献26

  • 1李键,周乐,刘智喜.Corey氧化剂在6－酮－17β－雌二醇合成中的应用[J].化学试剂,1994,16(5):317-318. 被引量：2
  • 2LYNN J. Fulvestrant ( ‘ Faslodex ) -a new hormonal treatmentfor advanced breast cancer [ J ] . Eur J Oncol Nurs f 2004, 8(Suppl 2) ;S83 -S88.
  • 3HONG YY, CHEN S. Aromatase, estrone sulfatase, and 17(3-hydroxysteroid dehydrogenase: Structure-function studies and in-hibitor development[ J] . Mol Cell Endocrinol, 2011 , 340(2):120 -126.
  • 4OSBORNE CK, WAKELING A, NICHOLSON RI. Fulvestrant:an oestrogen receptor antago-nist with a novel mechanism of ac-tion [J]. Br J Cancer, 2004,90 ( Suppl 1 ) :S2 - S6.
  • 5CAMERON DA, CAMIDGE DR, OYEE J, et al. Economic e-valuation of fulvestrant as an extra step in the treatment sequencefor ER-positive advanced breast cancer[ J]. Br J Cancer,2008,99(12):1984 -1990.
  • 6BRAZIER EJ, HOGAN PJ, POWELL L,et al. Fulvestrant:From the laboratory to commercial-scale manufacture [ J ]. OrgProcess Res Dev, 2010 , 4(3): 544 - 552.
  • 7PIROVANO S, ENNA L, ENNA R. rocess for 7a-[9-(4 ,4 ,5 ,5,5 -pentafluoropentylsulphinyl ) -nonyl ] estra-1,3,5-(10)-triene-3,17-beta-diol: W0, 013310[ P]. 2009 -01 -29.
  • 8MACDONALD PL, BIGATTI E,ROSSETTO P. A process forthe preparation of 7 a-alkylated 19-norsteroids : WO, 015081[P].2006 -09 -02.
  • 9PETTERSSON L. Steroids for cancer treatment: WO, 077968[PJ.2005 -08 -25.
  • 10FANG ZL, CUSHMAN M,AGOSTON GE , et al. Structure elu-cidation by synthesis of four metabolites of the antitumor drugENMD-1198 detected in human plasma samples [ J ]. Tetrahed-ron, 2009,65(51) : 10535 - 10543.

引证文献3

二级引证文献6

合成化学
2011年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部